What are the recommended dosing, monitoring, and management guidelines for using hydroxyurea in polycythemia vera?

Hydroxyurea in Polycythemia Vera: Dosing, Monitoring, and Management

Hydroxyurea remains the first-line cytoreductive therapy for high-risk polycythemia vera patients (age >60 years or history of thrombosis), with an initial dose of 15-20 mg/kg/day (or 500-1000 mg daily), titrated to maintain hematocrit <45% and control blood counts, while monitoring weekly CBCs for myelosuppression. 1, 2, 3

Initial Dosing Strategy

Start hydroxyurea at 15 mg/kg once daily (typically 500-1000 mg/day) rather than the higher loading doses previously used 3, 4. The FDA label specifies 15 mg/kg/day as the standard initial dose, though older protocols used 30 mg/kg/day loading doses which caused more early cytopenia 3, 4. Most patients in real-world practice receive maximum daily doses of 500-1000 mg, with only 6.4% requiring ≥2 g/day 5.

Key dosing adjustments:

• Renal impairment (CrCl <60 mL/min or ESRD): Reduce dose by 50% to 7.5 mg/kg/day 3
• On dialysis days, administer hydroxyurea after hemodialysis 3
• Titrate dose based on blood count response, not to exceed 2 g/day in most cases

Monitoring Requirements

Weekly complete blood counts are mandatory during hydroxyurea therapy 3. This intensive monitoring is critical because:

• Myelosuppression typically occurs within the first 8 weeks of therapy 4
• Severe anemia must be corrected before initiating treatment 3
• Monitor for dose-limiting cytopenias: ANC <1.0 × 10⁹/L, platelets <100 × 10⁹/L, or hemoglobin <10 g/dL 2

Treatment targets to monitor:

• Hematocrit <45% (primary goal to reduce thrombotic risk) 1, 2
• Platelet count ≤400 × 10⁹/L 2
• WBC count ≤10 × 10⁹/L 2

Common Pitfall: Inadequate Disease Control

Real-world data reveals substantial undertreatment: Among patients currently on hydroxyurea, 34-40% maintain hematocrit ≥45%, 59% have platelets >400 × 10⁹/L, and 58% have WBC >10 × 10⁹/L 5, 6. Two-thirds of patients have at least one elevated count, indicating inadequate dose titration 6. This represents a critical management failure—doses must be actively titrated upward (not simply maintained at starting doses) to achieve complete hematologic response.

Defining Hydroxyurea Resistance/Intolerance

Switch to second-line therapy (ruxolitinib or pegylated interferon) when patients meet ELN criteria for hydroxyurea resistance/intolerance 1, 2:

1. Need for phlebotomy to maintain hematocrit <45% after 3 months of ≥2 g/day hydroxyurea
2. Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months of ≥2 g/day
3. Failure to reduce massive splenomegaly by >50% after 3 months of ≥2 g/day
4. Cytopenia at lowest effective dose: ANC <1.0 × 10⁹/L, platelets <100 × 10⁹/L, or hemoglobin <10 g/dL
5. Unacceptable toxicity: leg ulcers, mucocutaneous manifestations, GI symptoms, pneumonitis, or fever at any dose 2

In real-world practice, 18.6% of patients discontinue hydroxyurea, most commonly due to adverse events/intolerance (37.1%) or lack of efficacy (35.5%) 5.

Second-Line Therapy Selection

For hydroxyurea-resistant/intolerant patients, both ruxolitinib and pegylated interferon are appropriate second-line options 1. The European LeukemiaNet provides a strong recommendation for ruxolitinib despite moderate-quality evidence, based on the RESPONSE trials showing 60% achieved hematocrit control without phlebotomy and 38% achieved ≥35% spleen volume reduction 1, 2.

Age-based algorithm for second-line choice:

• Young patients (<60 years) requiring long-term treatment: Prefer pegylated interferon 1
• Older patients: Either ruxolitinib or pegylated interferon acceptable; ruxolitinib may be preferred for convenience
• Very elderly patients: Consider intermittent busulfan 1

The rationale for preferring interferon in younger patients reflects the cautionary principle regarding long-term hydroxyurea exposure, though leukemic transformation risk remains debated 1.

Critical Safety Monitoring

Monitor for these specific toxicities requiring dose modification or discontinuation:

• Myelosuppression: Most common, usually transient in first 8 weeks 4
• Cutaneous vasculitis: Discontinue immediately and initiate treatment 3
• Leg ulcers: Indication for discontinuation at any dose 2
• Hemolytic anemia: If persistent, discontinue hydroxyurea 3
• In HIV patients on antiretrovirals: Monitor for pancreatitis, hepatotoxicity, and neuropathy 3

Prophylactic folic acid is recommended during hydroxyurea therapy 3.

Adjunctive Therapy

All patients require:

• Aspirin 81-100 mg daily (unless contraindicated) 2
• Phlebotomy as needed to maintain hematocrit <45% 2
• Aggressive cardiovascular risk factor management 1

Duration and Long-Term Considerations

Median hydroxyurea exposure in real-world practice is approximately 24 months, with 70% of patients continuing therapy at last follow-up 7. However, hydroxyurea does not adequately address clonal expansion or chronic inflammation—key drivers of thrombosis and disease progression 8. Unlike pegylated interferon or ruxolitinib, hydroxyurea has limited effect on reducing JAK2V617F variant allele frequency, suggesting weaker disease-modifying potential 8, 9.

Avoid live vaccinations in patients taking hydroxyurea 3.